Nutraponia Therapeutics
Nutraponia Therapeutics is a clinical-stage company focusing on developing oral therapeutics to address cancer pain and cachexia. The company's mission centers on improving quality of life for cancer patients by providing pain relief combined with nutritional support, filling significant unmet needs in cancer cachexia management. Its lead product candidate targets moderate to severe pain and aims to offer both analgesic efficacy and support for caloric intake.
Industries
N/A
Nutraponia Therapeutics
530d S. Henderson Rd. King of Prussia, PA 19406
Products
An oral liquid product in development aimed at providing moderate to severe pain relief alongside a structured, efficiently absorbed lipid nutrient matrix delivering approximately 100 kcal to support quality of life in cancer cachexia patients.
An oral liquid product in development aimed at providing moderate to severe pain relief alongside a structured, efficiently absorbed lipid nutrient matrix delivering approximately 100 kcal to support quality of life in cancer cachexia patients.
Services
Provides healthcare professionals with background scientific information, updates on product development, and opportunities for collaboration to address nutritional and pain management needs in cancer cachexia.
Provides healthcare professionals with background scientific information, updates on product development, and opportunities for collaboration to address nutritional and pain management needs in cancer cachexia.
Expertise Areas
- Cancer pain management
- Cachexia therapeutics
- Oral drug formulation
- Clinical trial management
Key Technologies
- Structured lipid formulation
- Opioid receptor agonism
- Oral liquid formulation
- Pharmacokinetic assessment
Key People
Founder
Chief Executive Officer
Finance
Chief Medical Officer
Founder
Chief Executive Officer
Finance
Chief Medical Officer
News & Updates
Presented new data and commercial strategies for the company's lead product candidate addressing cancer cachexia and associated pain.
Presented new data and commercial strategies for the company's lead product candidate addressing cancer cachexia and associated pain.